Karly P Garnock-jones

Publications77
h-index22
Citations1,749
Highly Influential Citations61
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • C. Confavreux
  • 321 Publications • 21,887 Citations
  • A. Coles
  • 276 Publications • 12,734 Citations
  • A. Mahableshwarkar
  • 50 Publications • 1,591 Citations
  • I. Laszlovszky
  • 162 Publications • 2,509 Citations
  • Publications
  • Influence
Ripasudil: First Global Approval
TLDR
The milestones in the development of ripasudil leading to the first approval for glaucoma and ocular hypertension are summarised.
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
TLDR
Once- or twice-daily atomoxetine was effective in the short-term treatment of ADHD in children and adolescents, as observed in several well designed placebo-controlled trials.
Panobinostat: First Global Approval
TLDR
The milestones in the development of panobinostat leading to this first approval for multiple myeloma are summarized.
Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
TLDR
Brentuximab vedotin was generally well tolerated in these trials; the most common adverse event was peripheral neuropathy; approximately one-half of patients with this adverse event experienced complete resolution.
Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
TLDR
Subcutaneous secukinumab is an effective and generally well tolerated first-line treatment for moderate to severe plaque psoriasis, and is a useful addition to the treatment options for this disease.
Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
TLDR
Esmolol, a cardioselective β-blocker, has been proven effective in the control of elevated haemodynamic parameters in patients with supraventricular tachyarrhythmia, hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease, as well as being associated with a reduced risk of some clinical sequelae to increased haemodynamics parameters.
Brexpiprazole: A Review in Schizophrenia
TLDR
Oral brexpiprazole 2–4 mg/day was generally effective in short-term, phase III studies at improving Positive and Negative Symptom Scale scores and other schizophrenia symptoms in patients with acute schizophrenia.
Cariprazine: A Review in Schizophrenia
TLDR
Cariprazine was generally well tolerated in clinical trials, with most adverse events being of mild to moderate severity, and metabolic changes observed were considered generally not clinically significant.
Vortioxetine: A Review of Its Use in Major Depressive Disorder
TLDR
It is well tolerated, but is associated with significantly increased sexual dysfunction at the highest dosage; however, vortioxetine was shown to improve previous-treatment-emergent sexual dysfunction in patients with well-treated MDD to a greater degree than escitalopram.
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
TLDR
Eltrombopag is an effective treatment option for adult patients with chronic ITP and an increased risk of bleeding who are refractory to previous treatments, including splenectomy, as demonstrated in well designed clinical trials.
...
1
2
3
4
5
...